Physician profile
Manar H Jbara
NPI 1912325242
$6,760.54
in general payments reported to CMS, 2019-2025
28 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.53 · 2020: $166 · 2021: $489 · 2022: $722 · 2023: $1,803 · 2024: $2,433 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750 · Travel and Lodging: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,749.75 |
| Travel and Lodging | $1,584.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,457.89 | 2021-2024 | Venaseal |
| Heartflow, INC. | $1,012.91 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $734.93 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $623.16 | 2020-2025 | Camzyos, Eliquis |
| Abiomed | $467.05 | 2021-2024 | Impella |
| Boston Scientific Corporation | $466.70 | 2022-2025 | General - Structural Heart, Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $357.93 | 2022-2025 | |
| Abbott Laboratories | $282.26 | 2022-2025 | Assurity, Gallant, Jot Dx |
| Pfizer INC. | $199.93 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.99 | 2019-2022 | |
| Elutia, INC. | $128.68 | 2022-2024 | Ecm Patch,Pouch |
| Lexicon Pharmaceuticals, INC. | $128.66 | 2023-2024 | Inpefa |
| Amgen INC. | $87.27 | 2023-2024 | Repatha |
| Lantheus Medical Imaging, INC. | $80.91 | 2023 | Definity |
| Actelion Pharmaceuticals US, INC. | $63.63 | 2022-2024 | Opsumit, Uptravi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $56.65 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $55.77 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $55.19 | 2020 | |
| Daiichi Sankyo INC. | $53.50 | 2023-2024 | Injectafer |
| Cardiva Medical, INC. | $46.93 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Scpharmaceuticals INC. | $45.43 | 2024 | |
| Janssen Pharmaceuticals, INC | $41.09 | 2021-2022 | |
| Irhythm Technologies, INC. | $34.17 | 2023-2024 | Zio Xt Patch |
| Vital Connect, INC | $33.39 | 2024 | Vitalpatch Rtm |
| Inspire Medical Systems, INC. | $23.40 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $21.62 | 2023 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $20.94 | 2023 | Arcalyst |
| Biogen, INC. | $18.56 | 2024 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manar Jbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.